Ascentage Pharma Group International

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ: AAPG - Get Free Report) have been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ: AAPG - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $15.40 and last traded at $15.1410, with a volume of 3803 shares trading hands. The stock had previously closed at $16.00. Wall Street Analyst

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in four upcoming investor conferences in New York, New York.

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript